XML 25 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and In-Process Research and Development
6 Months Ended
Sep. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]  
Goodwill and In-Process Research and Development

Note 6. Goodwill and In-Process Research and Development

 

The carrying amount of goodwill at September 30, 2017 and March 31, 2017 was $34.3 million and $31.0 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, in May 2005 and ECP and AIS in July 2014. The goodwill activity is as follows:

 

 

 

(in $000's)

 

Balance at March 31, 2017

 

$

31,045

 

Foreign currency translation impact

 

 

3,287

 

Balance at September 30, 2017

 

$

34,332

 

 

The Company evaluates goodwill and in-process research and development (“IPR&D”) assets at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable.  The Company has no accumulated impairment losses on goodwill or IPR&D assets.

The carrying amount of IPR&D assets at September 30, 2017 and March 31, 2017 was $16.0 million and $14.5 million, respectively, and has been recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014. The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows from the expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 21.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended September 30, 2017 are as follows:

 

 

 

(in $000's)

 

Balance at March 31, 2017

 

$

14,482

 

Foreign currency translation impact

 

 

1,534

 

Balance at September 30, 2017

 

$

16,016